AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUL 11 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Women with recurrent ovarian cancer may benefit from vaccination with the murine monoclonal anti-idiotypic antibody ACA125, say researchers working in Germany.
U. Wagner and colleagues discovered that the antibody ACA125, which imitates tumor-associated antigen CA125, could prolong survival in patients who had antibody responses to the vaccination.
Forty-two patients with recurrences that were pretreated with platinum received four immunizations with 2 mg of anti-idiotype ACA125 plus alum every two weeks, then monthly, in this Phase I/II clinical trial.
Twenty-eight of the subjects (66.7%) showed anti-idiotypic antibodies, reported Wagner and coworkers. These patients survived for 19.9 +/- 13.1 months compared with 5.3 +/- 4.3 months in patients without detectable anti-CA125 immunity, the researchers said.
None of the patients suffered serious allergic reactions to the vaccine ("Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment," Clinical Cancer Research, 2001;7(5):1154-1162).
"According to these results, vaccination with a suitable anti-idiotypic antibody offers an effective way to induce specific immunity ...
Source: HighBeam Research, Anti-idiotypic Antibody Vaccine May Prolong Survival.(Brief Article)